Analystreport

Can-Fite BioPharma (NYSE:CANF) had its price target lowered by analysts at D. Boral Capital from $11.00 to $4.00. They now have a "buy" rating on the stock.

Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com